Omeros/$OMER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omeros
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Ticker
$OMER
Sector
Primary listing
Employees
175
Headquarters
Website
Omeros Metrics
BasicAdvanced
$632m
7.23
$1.21
2.66
-
Price and volume
Market cap
$632m
Beta
2.66
52-week high
$17.65
52-week low
$2.95
Average daily volume
1.8m
Financial strength
Current ratio
3.034
Quick ratio
2.479
Long term debt to equity
-316.318
Total debt to equity
-357.797
Interest coverage (TTM)
-6.77%
Profitability
EBITDA (TTM)
-104.334
Gross margin (TTM)
-190.49%
Net profit margin (TTM)
871.02%
Operating margin (TTM)
-1,063.86%
Effective tax rate (TTM)
2.40%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-25.24%
Return on equity (TTM)
-60.68%
Valuation
Price to earnings (TTM)
7.226
Price to revenue (TTM)
59.136
Price to book
-9.93
Price to tangible book (TTM)
-9.93
Price to free cash flow (TTM)
4.029
Free cash flow yield (TTM)
24.82%
Free cash flow per share (TTM)
2.168
Growth
Earnings per share change (TTM)
-145.73%
10-year revenue growth (CAGR)
-7.05%
3-year earnings per share growth (CAGR)
17.53%
10-year earnings per share growth (CAGR)
-5.03%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Omeros News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs